Prognostic value of CD1B in localised prostate cancer

Cheng Hsueh Lee; Lih Chyang Chen; Chia Cheng Yu; Wen Hsin Lin; Victor C. Lin; Chao Yuan Huang; Te Ling Lu; Shu Pin Huang; Bo Ying Bao

doi:10.3390/ijerph16234723

Prognostic value of CD1B in localised prostate cancer

Cheng Hsueh Lee, Lih Chyang Chen, Chia Cheng Yu, Wen Hsin Lin, Victor C. Lin, Chao Yuan Huang, Te Ling Lu, Shu Pin Huang, Bo Ying Bao^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

14 Scopus citations

Abstract

Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09-1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification.

Original language	English
Article number	4723
Journal	International Journal of Environmental Research and Public Health
Volume	16
Issue number	23
DOIs	https://doi.org/10.3390/ijerph16234723
State	Published - 01 12 2019
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Biomarker
CD antigen
CD1B
Prognosis
Prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijerph16234723

Cite this

@article{08af32b97c5e48d09cd1cf37440ea327,

title = "Prognostic value of CD1B in localised prostate cancer",

abstract = "Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09-1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification.",

keywords = "Biomarker, CD antigen, CD1B, Prognosis, Prostate cancer",

author = "Lee, {Cheng Hsueh} and Chen, {Lih Chyang} and Yu, {Chia Cheng} and Lin, {Wen Hsin} and Lin, {Victor C.} and Huang, {Chao Yuan} and Lu, {Te Ling} and Huang, {Shu Pin} and Bao, {Bo Ying}",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

month = dec,

day = "1",

doi = "10.3390/ijerph16234723",

language = "英语",

volume = "16",

journal = "International Journal of Environmental Research and Public Health",

issn = "1661-7827",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "23",

}

TY - JOUR

T1 - Prognostic value of CD1B in localised prostate cancer

AU - Lee, Cheng Hsueh

AU - Chen, Lih Chyang

AU - Yu, Chia Cheng

AU - Lin, Wen Hsin

AU - Lin, Victor C.

AU - Huang, Chao Yuan

AU - Lu, Te Ling

AU - Huang, Shu Pin

AU - Bao, Bo Ying

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09-1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification.

AB - Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09-1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification.

KW - Biomarker

KW - CD antigen

KW - CD1B

KW - Prognosis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85075790718&partnerID=8YFLogxK

U2 - 10.3390/ijerph16234723

DO - 10.3390/ijerph16234723

M3 - 文章

C2 - 31783478

AN - SCOPUS:85075790718

SN - 1661-7827

VL - 16

JO - International Journal of Environmental Research and Public Health

JF - International Journal of Environmental Research and Public Health

IS - 23

M1 - 4723

ER -

Prognostic value of CD1B in localised prostate cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this